--- title: "Adaptive Trial Design, Definition | MedTech Terms" description: "Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/adaptive-trial#term", "name": "Adaptive Trial Design", "description": "Adaptive designs include group sequential, sample-size re-estimation, response-adaptive randomization, and adaptive enrichment. Modifications must be pre-specified to preserve Type I error and trial integrity.", "url": "https://medtechterms.com/terms/adaptive-trial", "termCode": "adaptive-trial", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/adaptive-trial#article", "headline": "Adaptive Trial Design", "description": "Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.", "url": "https://medtechterms.com/terms/adaptive-trial", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/adaptive-trial" }, "about": { "@id": "https://medtechterms.com/terms/adaptive-trial#term" }, "articleSection": "Clinical & Trials", "inLanguage": "en", "keywords": "Adaptive Trial Design, Clinical & Trials, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "FDA - Clinical Trials and Human Subject Protection", "url": "https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "ClinicalTrials.gov", "url": "https://clinicaltrials.gov/", "publisher": { "@type": "Organization", "name": "NIH" } }, { "@type": "CreativeWork", "name": "ICH Guidelines", "url": "https://www.ich.org/page/ich-guidelines", "publisher": { "@type": "Organization", "name": "ICH" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/bayesian-trial#term", "name": "Bayesian Trial Design", "url": "https://medtechterms.com/terms/bayesian-trial" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pivotal-trial#term", "name": "Pivotal Trial", "url": "https://medtechterms.com/terms/pivotal-trial" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Clinical & Trials", "item": "https://medtechterms.com/terms?cat=Clinical%20%26%20Trials" }, { "@type": "ListItem", "position": 4, "name": "Adaptive Trial Design", "item": "https://medtechterms.com/terms/adaptive-trial" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/adaptive-trial#faq", "mainEntity": [ { "@type": "Question", "name": "What is the primary benefit of an adaptive trial design?", "acceptedAnswer": { "@type": "Answer", "text": "The primary benefit is greater flexibility to modify trial aspects, such as sample size or treatment arms, based on accumulating data, potentially leading to more efficient and ethical studies." } }, { "@type": "Question", "name": "How do adaptive designs maintain statistical validity?", "acceptedAnswer": { "@type": "Answer", "text": "Statistical validity is maintained through careful pre-specification of adaptation rules and statistical methods that account for the modifications while controlling for Type I error." } }, { "@type": "Question", "name": "Are adaptive designs suitable for all types of clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "While offering advantages, adaptive designs are not suitable for all trials; their complexity and statistical requirements must be balanced against the specific research question and available resources." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Clinical & Trials](/terms?cat=Clinical%20%26%20Trials) 6. / 7. Adaptive Trial Design [All terms](/terms) Clinical & Trials [Clinical Evidence](/ecosystems/clinical-evidence) # Adaptive Trial Design Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Adaptive designs include group sequential, sample-size re-estimation, response-adaptive randomization, and adaptive enrichment. Modifications must be pre-specified to preserve Type I error and trial integrity. What the regulation says The FDA provides guidance on adaptive designs for clinical trials, emphasizing their potential benefits while also highlighting the need for careful planning and pre-specification of adaptation rules to maintain statistical validity and control Type I error. The EU [MDR](/terms/mdr-reporting) (Medical Device Regulation) and [IVDR](/terms/ivdr) (In Vitro Diagnostic Regulation) also implicitly support well-justified adaptive trial designs through their requirements for clinical evidence, provided that such designs are robust and scientifically sound. ## What this means in practice FDA actively encourages well-designed adaptive trials, especially in rare-disease and breakthrough device contexts. ## Examples - A sponsor conducting a pivotal trial for a novel cardiac stent pre-specifies criteria to re-estimate sample size at an interim analysis if the observed effect size is larger than initially assumed, thereby potentially reducing the overall trial duration. - A pharmaceutical company designing a Phase II oncology trial includes an adaptive enrichment strategy to focus enrollment on patient subgroups who show a better response to the investigational drug based on early interim data. - In a rare disease study, a manufacturer employs a response-adaptive randomization scheme, gradually assigning more patients to the treatment arm that demonstrates superior efficacy during the trial to maximize patient benefit. Common pitfalls - • Failing to pre-specify adaptation rules can compromise the integrity of the trial and lead to difficulties in regulatory acceptance. - • Inadequate justification for adaptations or poor statistical planning can result in biased outcomes or inflated Type I error rates. - • Overly complex adaptive designs can be difficult to implement and may introduce operational challenges. - • Failure to engage with regulatory bodies early in the planning of an adaptive trial may lead to delays or rejection of study results. - • Ignoring the potential impact of adaptations on blinding or randomization can undermine the validity of the trial. ## Frequently asked questions What is the primary benefit of an adaptive trial design? The primary benefit is greater flexibility to modify trial aspects, such as sample size or treatment arms, based on accumulating data, potentially leading to more efficient and ethical studies. How do adaptive designs maintain statistical validity? Are adaptive designs suitable for all types of clinical trials? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Clinical & Trials Pivotal Trial Definitive clinical study designed to establish safety and effectiveness for marketing authorization. ](/terms/pivotal-trial)[ Clinical & Trials Bayesian Trial Design Trial design that uses Bayesian statistics, often incorporating prior data from related studies or registries. ](/terms/bayesian-trial) ### Clinical Trials & Evidence · From this learning path [ Clinical & Trials Risk-Based Monitoring(RBM) Monitoring strategy that targets oversight resources to the highest-risk sites, processes, and data based on a documented risk assessment, replacing 100% source data verification. Adjacent lesson ](/terms/risk-based-monitoring?from=clinical-trials-and-evidence)[ Clinical & Trials Adverse Event(AE) Any untoward medical occurrence in a subject, whether or not related to the device. ](/terms/adverse-event?from=clinical-trials-and-evidence)[ Clinical & Trials Clinical Evaluation Report(CER) Documented assessment of clinical data demonstrating EU MDR conformity for a device. ](/terms/cer?from=clinical-trials-and-evidence)[ Clinical & Trials Feasibility Study Small clinical study evaluating initial safety, usability, and design parameters of an investigational device. ](/terms/feasibility-study?from=clinical-trials-and-evidence) ### More in Clinical & Trials · Same category [ Clinical & Trials IDE Annual Progress Report Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events. ](/terms/ide-annual-report)[ Clinical & Trials IDE Supplement Amendment to an approved Investigational Device Exemption for protocol or device changes. ](/terms/ide-supplement) Cited by Where this term appears across MedTech Terms. Learning paths (1) - [Clinical Trials & Evidence](/paths/clinical-trials-and-evidence)Lesson 15 of 18 Ecosystems (1) - [Clinical Evidence](/ecosystems/clinical-evidence) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 FDA· 1 NIH· 1 ICH· 1 1. [1 FDA - Clinical Trials and Human Subject Protection Verified FDA · fda.gov ](https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection) 2. [2 ClinicalTrials.gov Verified NIH · clinicaltrials.gov ](https://clinicaltrials.gov/) 3. [3 ICH Guidelines Verified ICH · ich.org ](https://www.ich.org/page/ich-guidelines) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Clinical evidence intersecting with device security? We support clinical-stage MedTech teams whose investigational devices touch patient data or hospital networks. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Clinical & Trials Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=adaptive-trial) Learn in 60 seconds Card Lesson Quiz Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data. - · FDA actively encourages well-designed adaptive trials, especially in rare-disease and breakthrough device contexts. - · Modifications must be pre-specified to preserve Type I error and trial integrity. Remember this Watch out: Failing to pre-specify adaptation rules can compromise the integrity of the trial and lead to difficulties in regulatory acceptance. Related terms - [Bayesian Trial Design ](/terms/bayesian-trial) - [Pivotal Trial ](/terms/pivotal-trial) You may also need Auto-suggested from Clinical & Trials and shared keywords. - [Sample Size and Statistical Power ](/terms/sample-size-power) - [Data Safety Monitoring Board(DSMB) ](/terms/dsmb) - [Electronic Data Capture(EDC) ](/terms/edc) - [Primary and Secondary Endpoints ](/terms/primary-secondary-endpoint) - [Early Feasibility Study(EFS) ](/terms/efs) - [Feasibility Study ](/terms/feasibility-study) [All Clinical & Trials terms](/terms?cat=Clinical%20%26%20Trials) From the Blue Goat network Related resources and services on this topic. - [ MedTech Launchpad MedTech funding rounds, accelerators, and launch resources. ](https://medtechlaunchguide.com) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)